Artiva Biotherapeutics, Inc. (ARTV)
NASDAQ: ARTV · Real-Time Price · USD
8.54
+0.54 (6.75%)
At close: Jun 12, 2026, 4:00 PM EDT
8.61
+0.07 (0.82%)
Pre-market: Jun 15, 2026, 7:39 AM EDT
Artiva Biotherapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
104
Market Cap
414.94M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 251.00K | -33.24M | -99.25% |
| Dec 31, 2023 | 33.49M | 28.56M | 579.21% |
| Dec 31, 2022 | 4.93M | 2.93M | 146.30% |
| Dec 31, 2021 | 2.00M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Century Therapeutics | 109.16M |
| Autolus Therapeutics | 92.62M |
| vTv Therapeutics | 36.84M |
| Ovid Therapeutics | 7.12M |
| Adlai Nortye | 5.00M |
| Ocugen | 4.47M |
ARTV News
- 6 days ago - Artiva Biotherapeutics Transcript: Status update - Transcripts
- 6 days ago - Artiva Biotherapeutics Press release: Status update - Filings
- 7 days ago - Artiva Biotherapeutics highlights AlloNK data presented at EULAR 2026 - TheFly
- 7 days ago - Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today - GlobeNewsWire
- 10 days ago - Artiva Biotherapeutics Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 17 days ago - Artiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference - GlobeNewsWire
- 26 days ago - Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at EULAR 2026 Congress, Including Late-Breaking Oral Presentation Highlighting Clinical Efficacy Comparable to Autologous CAR T-Cell Therapy in Rheumatologic Diseases - GlobeNewsWire
- 26 days ago - Artiva Biotherapeutics Appoints Veteran Biotech Executive and Drug Developer Diego Miralles, M.D., as President and Head of Research and Development - GlobeNewsWire